Adenosine pathway and cancer: Where do we go from here?

Luca Antonioli, G. Haskó, Matteo Fornai, Rocchina Colucci, Corrado Blandizzi

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Increasing evidence supports the occurrence of an intriguing link between tumor onset and development with the microenvironment in which cancer cells are embedded. In this context, a critical role of CD73, in calibrating the duration, magnitude and composition of adenosine signaling in cancer development and progression, has been identified. Adenosine levels are increased in cancer tissues as the result of genetic alterations that occur during tumor progression. Indeed, a rearrangement of the adenosine metabolic machinery has been described within the neoplastic milieu with the aim of amplifying adenosine generation, thereby creating an immune tolerant microenvironment suitable for tumor onset and development. At the same time, adenosine, through the engagement of receptors expressed on neoplastic cells, finely tunes the growth and dissemination of tumor mass, thus interfering with cancer proliferation, apoptosis and metastasis. Based on current knowledge, an improved understanding of how and to what extent adenosine participates to the molecular mechanisms underlying cancer development and diffusion will pave the way toward new therapeutic advances. The discovery and development of drugs targeted on this system might lead to substantial improvements in the clinical management of various cancers.

Original languageEnglish
Pages (from-to)973-977
Number of pages5
JournalExpert Opinion on Therapeutic Targets
Volume18
Issue number9
DOIs
Publication statusPublished - 2014

Fingerprint

Adenosine
Tumors
Neoplasms
Machinery
Tumor Microenvironment
Cells
Drug Discovery
Tissue
Apoptosis
Chemical analysis
Pharmaceutical Preparations
Neoplasm Metastasis
Growth

Keywords

  • Adenosine
  • Adenosine receptors
  • Cancer
  • CD73
  • Immune system
  • Inflammation
  • Novel therapies

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine
  • Medicine(all)

Cite this

Adenosine pathway and cancer : Where do we go from here? / Antonioli, Luca; Haskó, G.; Fornai, Matteo; Colucci, Rocchina; Blandizzi, Corrado.

In: Expert Opinion on Therapeutic Targets, Vol. 18, No. 9, 2014, p. 973-977.

Research output: Contribution to journalArticle

Antonioli, Luca ; Haskó, G. ; Fornai, Matteo ; Colucci, Rocchina ; Blandizzi, Corrado. / Adenosine pathway and cancer : Where do we go from here?. In: Expert Opinion on Therapeutic Targets. 2014 ; Vol. 18, No. 9. pp. 973-977.
@article{a1b88d87903f44ad99b2a6fb973c0214,
title = "Adenosine pathway and cancer: Where do we go from here?",
abstract = "Increasing evidence supports the occurrence of an intriguing link between tumor onset and development with the microenvironment in which cancer cells are embedded. In this context, a critical role of CD73, in calibrating the duration, magnitude and composition of adenosine signaling in cancer development and progression, has been identified. Adenosine levels are increased in cancer tissues as the result of genetic alterations that occur during tumor progression. Indeed, a rearrangement of the adenosine metabolic machinery has been described within the neoplastic milieu with the aim of amplifying adenosine generation, thereby creating an immune tolerant microenvironment suitable for tumor onset and development. At the same time, adenosine, through the engagement of receptors expressed on neoplastic cells, finely tunes the growth and dissemination of tumor mass, thus interfering with cancer proliferation, apoptosis and metastasis. Based on current knowledge, an improved understanding of how and to what extent adenosine participates to the molecular mechanisms underlying cancer development and diffusion will pave the way toward new therapeutic advances. The discovery and development of drugs targeted on this system might lead to substantial improvements in the clinical management of various cancers.",
keywords = "Adenosine, Adenosine receptors, Cancer, CD73, Immune system, Inflammation, Novel therapies",
author = "Luca Antonioli and G. Hask{\'o} and Matteo Fornai and Rocchina Colucci and Corrado Blandizzi",
year = "2014",
doi = "10.1517/14728222.2014.925883",
language = "English",
volume = "18",
pages = "973--977",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Adenosine pathway and cancer

T2 - Where do we go from here?

AU - Antonioli, Luca

AU - Haskó, G.

AU - Fornai, Matteo

AU - Colucci, Rocchina

AU - Blandizzi, Corrado

PY - 2014

Y1 - 2014

N2 - Increasing evidence supports the occurrence of an intriguing link between tumor onset and development with the microenvironment in which cancer cells are embedded. In this context, a critical role of CD73, in calibrating the duration, magnitude and composition of adenosine signaling in cancer development and progression, has been identified. Adenosine levels are increased in cancer tissues as the result of genetic alterations that occur during tumor progression. Indeed, a rearrangement of the adenosine metabolic machinery has been described within the neoplastic milieu with the aim of amplifying adenosine generation, thereby creating an immune tolerant microenvironment suitable for tumor onset and development. At the same time, adenosine, through the engagement of receptors expressed on neoplastic cells, finely tunes the growth and dissemination of tumor mass, thus interfering with cancer proliferation, apoptosis and metastasis. Based on current knowledge, an improved understanding of how and to what extent adenosine participates to the molecular mechanisms underlying cancer development and diffusion will pave the way toward new therapeutic advances. The discovery and development of drugs targeted on this system might lead to substantial improvements in the clinical management of various cancers.

AB - Increasing evidence supports the occurrence of an intriguing link between tumor onset and development with the microenvironment in which cancer cells are embedded. In this context, a critical role of CD73, in calibrating the duration, magnitude and composition of adenosine signaling in cancer development and progression, has been identified. Adenosine levels are increased in cancer tissues as the result of genetic alterations that occur during tumor progression. Indeed, a rearrangement of the adenosine metabolic machinery has been described within the neoplastic milieu with the aim of amplifying adenosine generation, thereby creating an immune tolerant microenvironment suitable for tumor onset and development. At the same time, adenosine, through the engagement of receptors expressed on neoplastic cells, finely tunes the growth and dissemination of tumor mass, thus interfering with cancer proliferation, apoptosis and metastasis. Based on current knowledge, an improved understanding of how and to what extent adenosine participates to the molecular mechanisms underlying cancer development and diffusion will pave the way toward new therapeutic advances. The discovery and development of drugs targeted on this system might lead to substantial improvements in the clinical management of various cancers.

KW - Adenosine

KW - Adenosine receptors

KW - Cancer

KW - CD73

KW - Immune system

KW - Inflammation

KW - Novel therapies

UR - http://www.scopus.com/inward/record.url?scp=84906240747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906240747&partnerID=8YFLogxK

U2 - 10.1517/14728222.2014.925883

DO - 10.1517/14728222.2014.925883

M3 - Article

C2 - 24958495

AN - SCOPUS:84906240747

VL - 18

SP - 973

EP - 977

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 9

ER -